EP1711168A2 - Oral pharmaceutical compositions of candesartan cilexetil - Google Patents

Oral pharmaceutical compositions of candesartan cilexetil

Info

Publication number
EP1711168A2
EP1711168A2 EP05702309A EP05702309A EP1711168A2 EP 1711168 A2 EP1711168 A2 EP 1711168A2 EP 05702309 A EP05702309 A EP 05702309A EP 05702309 A EP05702309 A EP 05702309A EP 1711168 A2 EP1711168 A2 EP 1711168A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
acid
composition according
candesartan cilexetil
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05702309A
Other languages
German (de)
French (fr)
Inventor
Romi Barat Singh
Girish K. S/o K.S. Karanth KARANTH
Vishnubhotla Naga Prasad
Sanjeev Kumar Sethi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1711168A2 publication Critical patent/EP1711168A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to pharmaceutical compositions of candesartan cilexetil and processes for their preparation.
  • Candesartan is a selective ATi subtype angiotensin II receptor antagonist.
  • angiotensin II receptor antagonists have attracted attention as effective agents for the treatment of hypertension in conjunction with angiotensin I converting enzyme (ACE) inhibitors.
  • ACE angiotensin I converting enzyme
  • Candesartan cilexetil is a prodrug that is hydrolyzed in the gastrointestinal tract during absorption to form candesartan. It falls in the class of benzimidazole -7- carboxylic acids and their derivatives. These agents exhibit a stronger and more effective hypotensive action when compared to other classes of ACE inhibitors. They also are less likely to cause coughing as a side effect.
  • Candesartan cilexetil is stable against temperature, moisture and light when it is alone in the solid state. However, when it is prepared into tablets and incorporated in with other ingredients, it has been observed that the active ingredient degrades over time.
  • U.S. Patent No. 5,534,534 discloses that the reduction in the content of the candesartan cilexetil with the lapse of time in pharmaceutical compositions can be reduced by incorporating oily substances having a low melting point in these compositions.
  • the oily substance is incorporated with the active component to form a stable composition that suppresses the decomposition over time that is caused by compression.
  • the resulting composition is described as being stable with minimal crystalline disorder.
  • the stability of pharmaceutical compositions of candesartan cilexetil can also be correlated to various degradation products, such as desethyl candesartan and other related substances. The levels of these related substances serve as a measure of the composition's overall stability.
  • a pharmaceutical composition that includes a candesartan cilexetil and one or more fatty substances being present at a concentration of about 0.5% to about 10% w/w.
  • the fatty substances may be lipids and phospholipids.
  • the lipids may be fatty acids and fatty acid esters.
  • the fatty acids may be one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof.
  • the fatty acid esters may be one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/ caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof.
  • the phospholipids may be phosphoglycerides and sphingolipids.
  • the phosphoglycerides maybe one or more of lecithin, cephalin, soyalecithin, egglecithin, phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
  • the candesartan cilexetil may be present in the pharmaceutical composition in a range of about 2% to about 35% w/w.
  • the composition may further include one or more pharmaceutically acceptable excipients.
  • the one or more pharmaceutically acceptable excipients maybe one or more of fillers, binders, disintegrants, lubricants, coloring and • flavoring agents.
  • the pharmaceutical composition may be in the form of a tablet or a capsule and the tablet may further include a coating, the coating including one or more functional and/or non-functional layers.
  • a process for the preparation of a pharmaceutical composition includes dispersing candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10%w/w in a binder solution to form a dispersion; granulating the dispersion with one or more fillers and the one or more disintegrants to form granules; and drying, sizing, lubricating and compressing the granules into tablets.
  • Embodiments of the process may include one or more of the following features or those described above.
  • the dispersion may f rther include one or more fillers.
  • the dispersion also may further include one or more disintegrants.
  • the granulation may be wet granulation and/or dry granulation.
  • a method for the treatment of hypertension in a patient in need thereof includes administering a pharmaceutical composition that includes candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10% w/w.
  • Embodiments of the method treatment may include one or more of the following features or those described above.
  • the fatty substances may include lipids and phospholipids.
  • the candesartan cilexetil may be present in a range of about 2% to about 35% w/w.
  • the present inventors have now surprising found that the use of fatty substances at a concentration of about 0.5% to about 10% w/w of the total composition results in stable pharmaceutical compositions of candesartan cilexetil. These pharmaceutical formulations have low levels of impurities, in particular desethyl candesartan and other related substances. Further, the present invention provides an economical method of stabilizing pharmaceutical compositions of candesartan cilexetil and enhances the shelf life of the product.
  • candesartan cilexetil refers to a prodrug that is hydrolyzed to form candesartan during its absorption from the gastrointestinal tract.
  • Candesartan cilexetil may be present at a concentration range of about 2% to about 35% w/w, and particularly from about 3% to about 30% w/w, based on the total weight of the composition.
  • the pharmaceutical composition of candesartan may also include one or more other active agents. Suitable other active agents include one or more diuretics, sympathoplegic agents, vasodilators, ACE inhibitors and angiotensin receptor antagonists. In each case, the other active agent may be in the free form or in the form of a pharmaceutically acceptable salt.
  • the term 'stabilized pharmaceutical composition' refers to a composition capable of maintaining excellent stability with respect to the levels of impurities, especially desethyl candesartan and other total related substances.
  • Suitable stabilizing agents include one or more fatty substances.
  • Suitable fatty substances include one or more of lipids, phospholipids and mixtures thereof.
  • Lipids include fatty acids and fatty acid esters.
  • the one or more fatty substance may be present in a concentration of about 0.5% to about 10% w/w, particularly from about 1% to about 5% w/w, based on the total weight of the composition.
  • Suitable fatty acids include one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof.
  • Suitable fatty acid esters include one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof.
  • Suitable phospholipids include phosphoglycerides, sphingolipids and mixtures thereof.
  • Suitabe phosphoglycerides include one or more of lecithin, cephalin, soyalecithin, egglecithin , phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
  • compositions described herein may also include one or more pharmaceutically acceptable excipients.
  • the pharmaceutical compositions may be prepared by processes known in the prior art, such as wet granulation, dry granulation and direct compression.
  • the pharmaceutical compositions may be in the form of tablets or capsules.
  • processes for the preparation of pharmaceutical compositions of candesartan cilexetil The process includes dispersing candesartan cilexetil and one or more fatty substances in the binder solution to form a dispersion.
  • the dispersion is then granulated with one or more fillers and one or more disintegrants to form granules.
  • the granules are then dried, sized, lubricated and compressed into tablets.
  • compositions of candesartan cilexetil may also be prepared by dispersing candesartan cilexetil, one or more fatty substances and one or more fillers in binder solution to form a dispersion.
  • the dispersion is then granulated with one or more fillers and one or more disintegrants.
  • the granules are then dried, sized, lubricated and compressed into tablets.
  • compositions of candesartan cilexetil may also may be prepared by dispersing candesartan cilexetil, one or more fatty substances and one or more distintegrants in a binder solution to form a dispersion. The dispersion then is granulated with one or more disintegrants and one or more fillers. The granules then are dried, sized, lubricated, and compressed into tablets.
  • Suitable pharmaceutically acceptable excipients include one or more of fillers, binders, disintegrants, lubricants, glidants, colors and mixtures thereof.
  • Suitable fillers include one or more of corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, sorbitol, starch, starch pregelatinized and mixtures thereof.
  • Suitable binders include one or more of methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol and mixtures thereof.
  • Suitable disintegrants include one or more of calcium carboxymethyl cellulose, colloidal silicon dioxide, starch, croscarmellose sodium, crospovidone, sodium starch glycolate and mixtures thereof.
  • Suitable lubricants and glidants include one or more of colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, white beeswax and mixtures thereof.
  • Suitable coloring agents include any FDA approved colors for oral use.
  • the tablets may also be coated with one or more additional layers of film forming agents and/or pharmaceutically acceptable excipients.
  • the coating layers over the tablet may be applied as a solution/dispersion of the coating ingredients using any conventional technique known in the prior art. Such processes include spray coating in a conventional coating pan or fluidized bed processor and dip coating. Suitable solvents used for preparing a solution/dispersion of the coating ingredients include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
  • Suitable film forming agents include one or more of ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methyl phthalate, cellulose acetate, cellulose acetate trimelliatate, cellulose acetate phthalate; waxes, such as polyethylene glycol; methacrylic acid polymers, such as Eudragit ® RL and RS; and mixture thereof.
  • commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry® may also be used for coating.
  • the following examples are illustrative of the invention, and are not to be construed as limiting the invention. EXAMPLE 1
  • Candesartan cilexetil and glyceryl caprate were dispersed in a solution of hydroxypropyl cellulose in water.
  • Candesartan cilexetil, glyceryl caprylate and a part of the lactose were dispersed in a solution of hydroxypropyl cellulose in water.
  • the wet granules were dried in a fluid bed drier, passed through a screen and then sized.
  • Candesartan cilexetil, soyalecithin and a part of the calcium carboxymethyl cellulose were dispersed in a solution of hydroxypropyl cellulose in water.
  • the magnesium stearate was then passed through a screen, blended with the blend of step 4 and the total mixture compressed into tablets.
  • the one or more fatty substances show a stabilizing effect on candesartan cilexetil.
  • Table 1 compares stability data at various intervals (40°C/75%RH) with reference to the amount of desethyl candesartan and total related substances found. TABLE 1
  • Table 1 indicates that the use of one or more fatty substances stabilizes the candesartan cilexetil compositions.

Abstract

The present invention relates to pharmaceutical compositions of candesartan cilexetil that include fatty substances and processes for their preparation.

Description

ORAL PHARMACEUTICAL COMPOSITIONS OF CANDESARTAN CILEXETIL
Technical Field of the Invention
The present invention relates to pharmaceutical compositions of candesartan cilexetil and processes for their preparation.
Background of the Invention
Candesartan is a selective ATi subtype angiotensin II receptor antagonist. In the field of hypertension thereapy, angiotensin II receptor antagonists have attracted attention as effective agents for the treatment of hypertension in conjunction with angiotensin I converting enzyme (ACE) inhibitors. Candesartan cilexetil is a prodrug that is hydrolyzed in the gastrointestinal tract during absorption to form candesartan. It falls in the class of benzimidazole -7- carboxylic acids and their derivatives. These agents exhibit a stronger and more effective hypotensive action when compared to other classes of ACE inhibitors. They also are less likely to cause coughing as a side effect. Candesartan cilexetil is stable against temperature, moisture and light when it is alone in the solid state. However, when it is prepared into tablets and incorporated in with other ingredients, it has been observed that the active ingredient degrades over time.
U.S. Patent No. 5,534,534 discloses that the reduction in the content of the candesartan cilexetil with the lapse of time in pharmaceutical compositions can be reduced by incorporating oily substances having a low melting point in these compositions.
According to the patent, the oily substance is incorporated with the active component to form a stable composition that suppresses the decomposition over time that is caused by compression. The resulting composition is described as being stable with minimal crystalline disorder. The stability of pharmaceutical compositions of candesartan cilexetil can also be correlated to various degradation products, such as desethyl candesartan and other related substances. The levels of these related substances serve as a measure of the composition's overall stability. Summary of the Invention
In one general aspect there is provided a pharmaceutical composition that includes a candesartan cilexetil and one or more fatty substances being present at a concentration of about 0.5% to about 10% w/w. Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the fatty substances may be lipids and phospholipids. The lipids may be fatty acids and fatty acid esters. The fatty acids may be one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof. The fatty acid esters may be one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/ caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof.
The phospholipids may be phosphoglycerides and sphingolipids. The phosphoglycerides maybe one or more of lecithin, cephalin, soyalecithin, egglecithin, phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
The candesartan cilexetil may be present in the pharmaceutical composition in a range of about 2% to about 35% w/w. The composition may further include one or more pharmaceutically acceptable excipients. The one or more pharmaceutically acceptable excipients maybe one or more of fillers, binders, disintegrants, lubricants, coloring and • flavoring agents. The pharmaceutical composition may be in the form of a tablet or a capsule and the tablet may further include a coating, the coating including one or more functional and/or non-functional layers.
In another general aspect there is provided a process for the preparation of a pharmaceutical composition. The process includes dispersing candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10%w/w in a binder solution to form a dispersion; granulating the dispersion with one or more fillers and the one or more disintegrants to form granules; and drying, sizing, lubricating and compressing the granules into tablets. Embodiments of the process may include one or more of the following features or those described above. For example, the dispersion may f rther include one or more fillers. The dispersion also may further include one or more disintegrants. The granulation may be wet granulation and/or dry granulation. In another general aspect there is provided a method for the treatment of hypertension in a patient in need thereof. The method includes administering a pharmaceutical composition that includes candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10% w/w.
Embodiments of the method treatment may include one or more of the following features or those described above. For example, the fatty substances may include lipids and phospholipids. The candesartan cilexetil may be present in a range of about 2% to about 35% w/w.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
Detailed Description of the Invention
The present inventors have now surprising found that the use of fatty substances at a concentration of about 0.5% to about 10% w/w of the total composition results in stable pharmaceutical compositions of candesartan cilexetil. These pharmaceutical formulations have low levels of impurities, in particular desethyl candesartan and other related substances. Further, the present invention provides an economical method of stabilizing pharmaceutical compositions of candesartan cilexetil and enhances the shelf life of the product.
The term candesartan cilexetil as used herein refers to a prodrug that is hydrolyzed to form candesartan during its absorption from the gastrointestinal tract. Candesartan cilexetil may be present at a concentration range of about 2% to about 35% w/w, and particularly from about 3% to about 30% w/w, based on the total weight of the composition. The pharmaceutical composition of candesartan may also include one or more other active agents. Suitable other active agents include one or more diuretics, sympathoplegic agents, vasodilators, ACE inhibitors and angiotensin receptor antagonists. In each case, the other active agent may be in the free form or in the form of a pharmaceutically acceptable salt.
The term 'stabilized pharmaceutical composition' refers to a composition capable of maintaining excellent stability with respect to the levels of impurities, especially desethyl candesartan and other total related substances.
Suitable stabilizing agents include one or more fatty substances. Suitable fatty substances include one or more of lipids, phospholipids and mixtures thereof. Lipids include fatty acids and fatty acid esters. The one or more fatty substance may be present in a concentration of about 0.5% to about 10% w/w, particularly from about 1% to about 5% w/w, based on the total weight of the composition.
Suitable fatty acids include one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof. Suitable fatty acid esters include one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof. Suitable phospholipids include phosphoglycerides, sphingolipids and mixtures thereof. Suitabe phosphoglycerides include one or more of lecithin, cephalin, soyalecithin, egglecithin , phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
These above stabilizing agents may be used alone or in a mixture of two or more of these agents. As described in more detail below, the compositions described herein may also include one or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be prepared by processes known in the prior art, such as wet granulation, dry granulation and direct compression. The pharmaceutical compositions may be in the form of tablets or capsules. Also provided are processes for the preparation of pharmaceutical compositions of candesartan cilexetil. The process includes dispersing candesartan cilexetil and one or more fatty substances in the binder solution to form a dispersion. The dispersion is then granulated with one or more fillers and one or more disintegrants to form granules. The granules are then dried, sized, lubricated and compressed into tablets.
The pharmaceutical compositions of candesartan cilexetil may also be prepared by dispersing candesartan cilexetil, one or more fatty substances and one or more fillers in binder solution to form a dispersion. The dispersion is then granulated with one or more fillers and one or more disintegrants. The granules are then dried, sized, lubricated and compressed into tablets.
Pharmaceutical compositions of candesartan cilexetil may also may be prepared by dispersing candesartan cilexetil, one or more fatty substances and one or more distintegrants in a binder solution to form a dispersion. The dispersion then is granulated with one or more disintegrants and one or more fillers. The granules then are dried, sized, lubricated, and compressed into tablets.
The term 'other pharmaceutically acceptable excipient' refers to ingredients of the composition, excluding the active drug substance. Suitable pharmaceutically acceptable excipients include one or more of fillers, binders, disintegrants, lubricants, glidants, colors and mixtures thereof. Suitable fillers include one or more of corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, sorbitol, starch, starch pregelatinized and mixtures thereof.
Suitable binders include one or more of methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol and mixtures thereof. Suitable disintegrants include one or more of calcium carboxymethyl cellulose, colloidal silicon dioxide, starch, croscarmellose sodium, crospovidone, sodium starch glycolate and mixtures thereof.
Suitable lubricants and glidants include one or more of colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, white beeswax and mixtures thereof.
Suitable coloring agents include any FDA approved colors for oral use.
The tablets may also be coated with one or more additional layers of film forming agents and/or pharmaceutically acceptable excipients.
The coating layers over the tablet may be applied as a solution/dispersion of the coating ingredients using any conventional technique known in the prior art. Such processes include spray coating in a conventional coating pan or fluidized bed processor and dip coating. Suitable solvents used for preparing a solution/dispersion of the coating ingredients include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
Suitable film forming agents include one or more of ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methyl phthalate, cellulose acetate, cellulose acetate trimelliatate, cellulose acetate phthalate; waxes, such as polyethylene glycol; methacrylic acid polymers, such as Eudragit ® RL and RS; and mixture thereof. Alternatively, commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry® may also be used for coating. The following examples are illustrative of the invention, and are not to be construed as limiting the invention. EXAMPLE 1
PROCEDURE:
1. Candesartan cilexetil and glyceryl caprate were dispersed in a solution of hydroxypropyl cellulose in water.
2. Lactose, starch and a part of the calcium carboxymethyl cellulose were mixed in a high shear mixer and granulated with the dispersion of Step 1.
3. The wet granules were then dried in a fluid bed drier, passed through a screen and then sized. 4. The remaining part of the calcium carboxymethyl cellulose was passed through a screen and blended with the granules of step 3.
5. The magnesium stearate was then passed through a screen, blended with the blend of step 4 and the total mixture compressed into tablets. EXAMPLE 2
PROCEDURE:
1. Candesartan cilexetil, glyceryl caprylate and a part of the lactose were dispersed in a solution of hydroxypropyl cellulose in water.
2. The remaining part of lactose, microcrystalline cellulose, a part of calcium carboxymethyl cellulose and colloidal silicon dioxide were mixed in a high shear mixer and granulated with the dispersion of Step 1.
3. The wet granules were dried in a fluid bed drier, passed through a screen and then sized.
4. The remaining quantity of calcium carboxymethyl cellulose was passed through a screen and blended with the granules of step 3.
5. The magnesium stearate then was passed through a screen, blended with the blend of step 4 and the total mixture compressed into tablets. EXAMPLE 3
PROCEDURE:
1. Candesartan cilexetil, soyalecithin and a part of the calcium carboxymethyl cellulose were dispersed in a solution of hydroxypropyl cellulose in water.
2. The starch, lactose and colloidal silicon dioxide were mixed in a high shear mixer and granulated with the dispersion of Step 1.
3. The wet granules were dried in a fluid bed drier, passed through a screen and then sized. 4. The remaining part of the calcium carboxymethyl cellulose was passed through a screen and blended with the granules of step 3.
5. The magnesium stearate was then passed through a screen, blended with the blend of step 4 and the total mixture compressed into tablets.
The one or more fatty substances show a stabilizing effect on candesartan cilexetil. Table 1 compares stability data at various intervals (40°C/75%RH) with reference to the amount of desethyl candesartan and total related substances found. TABLE 1
Table 1 indicates that the use of one or more fatty substances stabilizes the candesartan cilexetil compositions.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.

Claims

WE CLAIM:
1. A pharmaceutical composition comprising candesartan cilexetil and one or more fatty substances being present at a concentration of about 0.5% to about 10% w/w.
2. The pharmaceutical composition according to claim 1, wherein the fatty substances comprise lipids and phospholipids.
3. The pharmaceutical composition according to claim 2, wherein the lipids comprise fatty acids and fatty acid esters.
4. The pharmaceutical composition according to claim 3, wherein the fatty acids comprises one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof.
5. The pharmaceutical composition according to claim 3, wherein the fatty acid esters comprise one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/ caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof.
6. The pharmaceutical composition according to claim 2, wherein the phospholipids comprise phosphoglycerides and sphingolipids.
7. The pharmaceutical composition according to claim 6, wherein the phosphoglycerides comprise one or more of lecithin, cephalin, soyalecithin, egglecithin, phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
8. The pharmaceutical composition according to claim 1, wherein the candesartan cilexetil is present in a range of about 2% to about 35% w/w.
9. The pharmaceutical composition according to claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients.
10. The pharmaceutical composition according to claim 9, wherein the one or more pharmaceutically acceptable excipients comprise one or more of fillers, binders, disintegrants, lubricants, coloring and flavoring agents.
11. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in the form of a tablet or a capsule.
12. The pharmaceutical composition according to claim 11 , wherein the tablet further comprises a coating comprising one or more functional and/or non-functional layers.
13. A process for the preparation of a pharmaceutical composition, the process comprising: dispersing candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10%w/w in a binder solution to form a dispersion; granulating the dispersion with one or more fillers and the one or more disintegrants to form granules; and drying, sizing, lubricating and compressing the granules into tablets.
14. The process according to claim 13, wherein the dispersion further includes one or more fillers.
15. The process according to claim 13, wherein the dispersion further includes one or more disintegrants.
16. The process according to claim 13, wherein the granulation comprises wet granulation and/or dry granulation.
17. A method for the treatment of hypertension in a patient in need thereof, the method comprising administering a pharmaceutical composition comprising candesartan cilexetil and one or more fatty substances at a concentration of about 0.5%) to about 10% w/w.
18. The method of treatment according to claim 17, wherein the fatty substances comprise lipids and phospholipids.
19. The method of treatment according to claim 17, wherein the candesartan cilexetil is present in a range of about 2% to about 35% w/w.
EP05702309A 2004-01-23 2005-01-21 Oral pharmaceutical compositions of candesartan cilexetil Withdrawn EP1711168A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN127DE2004 2004-01-23
PCT/IB2005/000148 WO2005079751A2 (en) 2004-01-23 2005-01-21 Oral pharmaceutical compositions of candesartan cilexetil

Publications (1)

Publication Number Publication Date
EP1711168A2 true EP1711168A2 (en) 2006-10-18

Family

ID=34878773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05702309A Withdrawn EP1711168A2 (en) 2004-01-23 2005-01-21 Oral pharmaceutical compositions of candesartan cilexetil

Country Status (2)

Country Link
EP (1) EP1711168A2 (en)
WO (1) WO2005079751A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165702A1 (en) 2008-09-17 2010-03-24 Helm AG Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI494134B (en) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag Composition granule and tablet containing candesartan cilexetil and process to fabricate the tablet
AU2007293727A1 (en) * 2006-09-05 2008-03-13 Astrazeneca Ab Pharmaceutical composition comprising candesartan cilexetil
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
US20100041644A1 (en) * 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
PL384680A1 (en) * 2007-03-28 2008-09-29 Zak & Lstrok Ady Farmaceutyczn Pharmaceutical composition containing cylexyethyl candesarthan and its production method
US20090048317A1 (en) * 2007-08-01 2009-02-19 Michael Fox Formulations of candesartan
DE102007052070A1 (en) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg candesartancilexetil
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
ES2364011B1 (en) 2009-11-20 2013-01-24 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
PT2663294E (en) 2011-01-11 2016-01-25 Capsugel Belgium Nv New hard capsules comprising pullulan
WO2013167453A1 (en) 2012-05-07 2013-11-14 Bayer Pharma Aktiengesellschaft Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
CN103127012B (en) * 2013-02-17 2015-04-22 杭州澳医保灵药业有限公司 Ebastine dispersible tablet and preparation method thereof
JP2020516653A (en) 2017-04-14 2020-06-11 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ Pullulan capsule
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
CN117442577B (en) * 2023-12-21 2024-03-15 山东则正医药技术有限公司 Candesartan cilexetil microchip and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW284688B (en) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
DE19820151A1 (en) * 1998-05-06 1999-11-11 Hexal Ag Transdermal therapeutic system for the application of candesartan
ATE487491T1 (en) * 1999-02-19 2010-11-15 Takeda Pharmaceutical PREPARATIONS FOR THE PERCUTANE ADMINISTRATION OF COMPOSITIONS THAT HAVE AN ANGIOTENSIN II RECEPTOR ANTAGONISM
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005079751A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165702A1 (en) 2008-09-17 2010-03-24 Helm AG Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation

Also Published As

Publication number Publication date
WO2005079751A3 (en) 2006-03-30
WO2005079751A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
EP1711168A2 (en) Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) Pharmaceutical compositions comprising candesartan cilexetil
JP2021178871A (en) Formulations of enzalutamide
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
JPWO2009066773A1 (en) Orally disintegrating tablets
WO2005070398A2 (en) Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
KR20130091319A (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
WO2014090386A1 (en) Orally disintegrating tablet containing asenapine
EP3606511A1 (en) Pharmaceutical composition comprising lenvatinib mesylate
JP7322475B2 (en) Tablets containing azilsartan
US20040037880A1 (en) Extended release formulation of divalproex sodium
WO2012147101A2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
KR20100083047A (en) Valsartan pharmaceutical compositions having improved bioavailability
MX2015004973A (en) Formulations of pyrimidinedione derivative compounds.
WO2019180735A1 (en) Stable pharmaceutical compositions comprising sacubitril-valsartan complex
WO2008118031A1 (en) Pharmaceutical composition comprising candesartan cilexetil and method for manufacturing thereof
JP7322474B2 (en) Tablets containing azilsartan
WO2006013444A1 (en) Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
JP3597823B2 (en) Solid preparation
EP2153822A1 (en) Granulation of active pharmaceutical ingredients
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2008068727A2 (en) Pharmaceutical composition comprising candesartan cilexetil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17P Request for examination filed

Effective date: 20061002

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070801